Study Group: Zofran Prescribers (US)(?)
Council Members in this Study Group: 36
Request a survey with this Study Group
Leading Experts in this Study Group
Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Chairman of Anesthesiology and Critical Care
Westgate Medical Anesthesia Group
Sabry Ayad, MD, is a member of Westgate Medical Anesthesia Group, a private practice that provides a full range of anesthesia services for local healthcare facilities in Ohio. Through his employment at Westgate Medical Anesthesia Group, he is the Chairman of Anesthesiology and Critical Care at Fairview...
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...
Assistant Professor of Medicine
New York University School of Medicine/ Medical Center
James D'Olimpio, MD, FACP, is the Director of Palliative Medicine/Cancer Pain and Supportive Oncology at North Shore University Hospital/Monter Cancer Center in Manhasset, New York, and an Assistant Professor of Medicine at New York University School of Medicine. His expertise includes a wide range...
Haitham Al-Okk, MDAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center
Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...
Professor, Department Chair
Stanford University School of Medicine
Jonathan Berek, MD, MMS, is a Professor and Department Chair of Obstetrics and Gynecology at Stanford University School of Medicine, California. He is the Chief of Obstetrics and Gynecology at Stanford University Hospital and Clinics. Dr. Berek is also the Group Chair of Cooperative Ovarian Cancer...
Related Study Groups
| Study Group Name | Members |
|---|---|
| SRA Prescribers (US) | 47 |
| Oncologists (US) | 2247 |
| Aloxi Prescribers for CINV (US) | 38 |
| Aloxi Prescribers for CINV: Oncologists (US) | 47 |
| Hematologists (US) | 1019 |
| Oncologists who Treat Hematologic Malignancies (US) | 881 |
| Physicians who Treat Multiple Myeloma (US) | 171 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
The author argues that transparency in healthcare will be an important step forward for the consumer.
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes. Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Physician - Department Chair
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms